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Bioconcentrationa b s t r a c t
Tests with vertebrates are an integral part of environmental hazard identification and risk assessment of
chemicals, plant protection products, pharmaceuticals, biocides, feed additives and effluents. These tests
raise ethical and economic concerns and are considered as inappropriate for assessing all of the sub-
stances and effluents that require regulatory testing. Hence, there is a strong demand for replacement,
reduction and refinement strategies and methods. However, until now alternative approaches have only
rarely been used in regulatory settings. This review provides an overview on current regulations of chem-
icals and the requirements for animal tests in environmental hazard and risk assessment. It aims to high-
light the potential areas for alternative approaches in environmental hazard identification and risk
assessment. Perspectives and limitations of alternative approaches to animal tests using vertebrates in
environmental toxicology, i.e. mainly fish and amphibians, are discussed. Free access to existing (proprie-
tary) animal test data, availability of validated alternative methods and a practical implementation of
conceptual approaches such as the Adverse Outcome Pathways and Integrated Testing Strategies were
identified as major requirements towards the successful development and implementation of alternative
approaches. Although this article focusses on European regulations, its considerations and conclusions
are of global relevance.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Animal tests are an integral part of environmental hazard
identification and risk assessment of industrial chemicals, plant
protection products, biocides, feed additives and pharmaceuticals.
They are also used to monitor the quality of effluents and surface
waters to improve the assessment of the status of European waters
under the auspices of the Water Framework Directive (EU, 2000).
Depending on intended use, diverse regulations are applied thatrequire different types of animal tests. This has raised ethical
concerns with regard to tests using vertebrates in environmental
risk assessment (mainly fish, amphibians, and birds; occasionally,
mammals are used, for example for testing of rodenticides
and plant protection products, EU, 2013, 2012c). Ethical concerns
– according to European regulation (EU, 2010a) – apply also to
cephalopods, but these are not commonly used in environmental
risk assessment. Even though many regulatory frameworks
principally encourage the use of alternative approaches such as
508 S. Scholz et al. / Regulatory Toxicology and Pharmacology 67 (2013) 506–530(Q) SAR ((Quantitative) Structure–Activity Relationships), read-
across, or alternative experimental test methods, there is
opportunity to expand on the range of models, and domain of
applicability30 using new data, and both scientific and technological
advancements in the field. The use of alternative experimental test
methods has been limited to date. A main reason – as discussed in
detail in this review – is not a lack of available methods, but a lack
of consensus on their applicability domains and international
validation and regulatory acceptance including appropriate OECD
(Organisation for Economic Co-operation and Development) test
guidelines. With regard to the daily use of alternatives to animal
testing, the field of human health hazard and risk assessment of
chemicals seems to be more advanced, since for certain areas such
as skin corrosion and irritation animal tests have been fully replaced
by alternative testing methods and have already been implemented
in European legal frameworks such as REACH (Registration, Evalua-
tion, Authorisation and Restriction of Chemicals) and the Cosmetics
Regulation (EU, 2006, 2009b).
The purpose of this review paper is to highlight the potential
areas for alternative approaches in environmental hazard and risk
assessment, including present limitations, as well as perspectives
for further developments and subsequent implementations.
2. Legal framework
In the European Union (EU), chemicals31 are assessed under dif-
ferent legislative instruments (by substance type) with respect to
their risks to humans and the environment (Table 1). Most industrial
chemicals are regulated by the European Union regulation on
chemicals and their safe use (EU, 2006) commonly known as REACH.
Specific regulations exist for plant protection products (EU, 2009a,
2013), biocidal products (EU, 1998, 2012c), medicinal products for
human and veterinary use (EMA/CHMP, 2006; EMA/CVMP, 2008)
and feed additives (EU, 2003, 2008a). The environmental concerns
raised by substances used in cosmetic products are considered
through REACH (EU, 2009b).
The testing schemes and guidelines used in these different
European regulations are strongly driven by international activi-
ties, mainly by the OECD, aiming at the harmonisation of testing
and regulations (Koëter, 2003). The OECD provides harmonised
test guidelines as a basis for the mutual acceptance of data prin-
ciple, avoiding duplicative testing and costs by international
sharing the burden of hazard assessment. Furthermore, the
WHO, through the Global Harmonisation System (UN, 2011),
has impacted on European regulation and animal testing via
the CLP Directive (directive on classification, labeling and pack-
aging of substances and mixtures; EU, 2009c), which is closely
interlinked with REACH and the regulation of plant protection
and biocidal products. In all the different regulations, the recom-
mended testing procedures refer to OECD testing guidelines
(Table 1).
To bring a new chemical substance/product to market re-
quires in most cases that both the active compound and the final
commercial product are shown to be safe for the environment.
Therefore, an Environmental Risk Assessment (ERA) is included
in the information dossier submitted to the relevant regulatory
body. The specific regulations for the various types of substances30 The applicability domain is the physico-chemical, structural or biological space,
for which alternative testing approaches are applicable to make predictions. Even in
case of limitations of alternative approaches, they may be still applied if this domain
is clearly defined. Consequently, for compounds outside the applicability domain,
hazard and risk assessment has to be based on established in vivo experimental or
other alternative approaches.
31 The term ‘‘chemical’’ as used in this article refers to a chemical compound in
general and – unless otherwise indicated – regardless of the potential application in
industry, household, agriculture or medicine.(industrial chemicals, pesticides, biocides, feed additives, phar-
maceuticals) require the same type of animal testing, and refer
to the same OECD testing guidelines (see Table 1). What
distinguishes the different regulations are the thresholds and
constraints as to when a specific test is required. Furthermore,
the different regulations also address the distribution of a chem-
ical into different environmental compartments, such as soil or
surface water, and the resulting different exposure routes. Hence,
testing of some classes of vertebrates, such as birds, is only
required in some regulations (e.g. for plant protection products)
and with relevance to the expected fate and exposure of the
compound (Table 1).
Testing on fish is required to provide data on short-term and
long-term aquatic toxicity. Additional studies may be triggered to
assess bioaccumulation in fish (dependent on hydrophobicity,32
persistence and toxicity) and for identifying endocrine-disrupting
chemicals (formal regulatory definitions for these compounds
and triggers for testing are yet to be defined). A general strategy
to integrate acute toxicity, chronic toxicity, bioaccumulation and
endocrine disruption endpoints for fish was developed by OECD
under the Fish Toxicity Testing Framework Program (OECD,
2012b). This OECD initiative includes scope for where alternative
assays are or could be implemented. For the terrestrial environ-
ment, short- and long-term testing or testing of reproductive
toxicity to birds is required for plant protection products, when
a potential exposure is expected. Avian testing is required under
REACH at high tonnage levels (>1000 t/a). However, given the
large mammalian dataset available at this tonnage level, waiving
of tests is often permitted and mammalian data are accepted as
surrogates for non-mammalian tests. Under certain circumstances,
testing of mammals may be considered in environmental risk
assessment of plant protection and biocidal products, in order to
assess the potential risk of so-called secondary poisoning, i.e. by
accumulation via the food chain and from dietary exposure to con-
taminated food (EU, 2013, 2012c). However, usually the appropri-
ate data would be already available from studies that had to be
conducted for human hazard assessment. In the aquatic environ-
ment, uptake from food is not considered relevant for compounds
with a logKow (octanol–water partition coefficient) < 4 (Gobas
et al., 2009).
There are also specific requirements for chemicals used offshore
by OSPAR (Oslo and Paris convention, http://www.ospar.org/), a
legislative instrument by which fifteen Governments of the
western coasts and catchments of Europe, together with the EU,
cooperate to protect the marine environment of the North-East
Atlantic. OSPAR has established a Harmonised Offshore Chemical
Notifications Format (HOCNF) which, under certain circumstances
(Table 1), requires provision of acute fish toxicity and fish biocon-
centration data (OSPAR, 2012).
Not only individual chemicals and their products, under some
situations, are required to be tested for potential risk to the
environment. Industrial effluents in the EU Member States are also
subject to control for potential toxic effects to organisms in the
environment, including water, sediment, soil and air. As stated in
the Directive on Industrial Emissions Integrated Pollution
Prevention and Control (IED) (EU, 2010b), industrial activities
require an environmental permit, including a description of
‘‘the nature and quantities of foreseeable emissions from the2 Hydrophobicity and lipophilicity are often understood as synonyms, particularly
the context of bioaccumulation. Considering the fact that for organic compounds
eir affinity to water varies by orders of magnitude more than their affinity to lipid
r associated surrogates such as octanol, it is typically the former that drives the
assive partitioning of xenobiotics from water into lipid. Accordingly, we prefer the
rm hydrophobicity, and interpret the octanol/water partition coefficient Kow as








Summary of European Union (EU) regulatory frameworks that require animal testing for environmental hazard and risk assessment. For comparison and in order to indicate that similar frameworks exist outside the EU, the appropriate
regulatory framework of the United States of America (USA) has been included. Requirements for the conduct of the specific tests were taken from the appropriate pieces of legislation and/or the OECD fish toxicity testing framework
(OECD, 2012b). Legislations were abbreviated (see legend).
Test type/OECD guideline (or US EPA if appropriate) Regulatory framework Number of animals
[typical design] needed




OECD 203 and OCSPP 850.1075: Fish acute toxicity
test (US EPA, 1996a; OECD, 1992; US EPA, 2002)
REACH. Required for compounds produced or imported >10 tonnes/year
(conditional waiving is possible).
TSCA: Conditional requirement 42
PPP. Mandatory for rainbow trout (threshold approach) FIFRA: Cold and warm water freshwater species and 1 saltwater species
BioP. Mandatory for one freshwater species (and marine species if
relevant)(threshold approach).
FFDCA: Tier 2 testing of drugs and biologicals for refinement of
assessment factors (US FDA, 1998)
VMP. Mandatory for Tier A.
FA.Required if PEC in surface water P 0.1 lg/L or in sediments P 10 lg/kg.
HOCNF. Mandatory if not tested already under REACH. A limit test can be
used instead of a full acute fish toxicity test.
Effluent testing Sweden (Naturvårdsverket, 2010) (OSPAR, 2000) Denmark,
France, Ireland, Norway (OSPAR, 2000)
Effluent testing Clean Water Act (US Congress 33 U.S.C. 1251)
Generally, a detailed guidance when acute fish toxicity should be assessed for
effluents is missing. Acute fish tests are often required if ‘‘available data and
experience is insufficient’’(OSPAR, 2000)
Specific requirements for effluent testing vary on a state and regional
basis and are usually defined within discharge permits.
OECD 223 Avian acute oral toxicity test PPP. Mandatory except where the active substance is intended solely to be
included in preparations for exclusive use in enclosed spaces (e.g. in glasshouses
or in food storage practice)
TSCA FIFRA, mandatory (in multiple species including a passerine) 44 (Number is variable
and depending on the
dose–response
observed. The number
refers to a mean from
an analysis of Syngenta
and Dow data)
BioP. The acute oral toxicity of active substance to a quail or to mallard duck
must be determined, except where the active substance is intended solely to be
included in preparations for exclusive use in enclosed spaces.
FA. Optional for refinement of assessment factors in case that PEC groundwater
P 0.1 lg/L or PEC soil P 10 lg/kg
OECD 205 or OCSPP 850.2200 Avian Dietary
Toxicity Test




OECD 210 OCSPP 850.1400: Fish Early Life-Stage
test
REACH. Required for chemicals produced or imported >100 tonnes/year if the
chemical safety assessment indicates the need to further investigate effects on
aquatic organisms. The need may be indicated by a PEC/PNEC ratio above 1, but
also by information concerning high acute to chronic ratios of structural
analogues or physical–chemical parameters indicating poor water solubility or a
high bioconcentration potential.
TTSCA. Conditional requirement 420
PPP. Always required if exposure of surface water is likely and the compound is
stable in water (<90% loss over 24 h by hydrolysis)
FIFRA. Required for fresh-water species; conditionally required in
saltwater species
BioP. Required for PNEC (predicted no effect concentration) refinement.
HMP. Required for Phase II Tier A.
VMP. Required for Phase II Tier B.
Effluent testing Sweden (Naturvårdsverket, 2010): Conditional based on the
outcome of acute tests and PEC/PNEC > 1 (based on available data of
components).
Effluent testing Clean Water Act (US Congress 33 U.S.C. 1251).
Specific requirements for effluent testing vary on a state and regional
basis and are usually defined within discharge permits.















Test type/OECD guideline (or US EPA if appropriate) Regulatory framework Number of animals
[typical design] needed
for testing of one
compound/sample
Europe USA
OECD 215 Fish, Juvenile Growth test REACH. Can be performed instead of the Fish Early Life-Stage Test or Fish, Short-
term Toxicity Test on Embryo and Sac-Fry Stages.
n.r. n.a.
PPP. Only required if Fish Early Life Stage Test or Fish Full Life Cycle Test are not
appropriate.
BioP. Required for PNEC refinement (if log Kow < 5).
OECD 212: Fish, Short-term Toxicity Test on
Embryo and Sac-Fry Stages




Fish full life cycle test (not yet internationally
standardised, Crane et al., 2010; US EPA, 1998)
PPP: Conditionally required in cases where the bioconcentration factor is
greater than 1000 and the elimination of the active substance during a
depuration phase of 14 days is lower than 95%, or the substance is stable in
water or sediment (DT90 > 100 days) (CTGB, 2013).
FIFRA: conditionally required if estimated environmental
concentration P 0.1 FELS NOEC or studies of other organisms
indicate the reproductive physiology of fish may be affected (US
EPA, 1996b).
n.a.
Avian reproduction test (OECD TG 206, US-EPA
OCSPP 850.2300)) (US EPA, 2012;OECD, 1984)
REACH. Conditionally required for chemicals produced or imported
>1000 tonnes/year. Any need for testing should be carefully considered taking
into account the large mammalian dataset that is usually available at this
tonnage level
TSCA, FIFRA, FFDCA Mandatory for two species 96
PPP. Always mandatory for two species
Bioconcentration
OECD 305 and OCSPP 850.1730. Bioconcentration:
Flow-through fish test
REACH. Required for chemicals produced or imported in over 100 Ton/year and
log Kow P 3
TSCA. Conditional requirement 108
PPP. Required for products with log Kow > 3 and considered stable. FIFRA. Conditional requirement
BioP. Required for anti-foulings, detergents and if log Kow P 3.
HMP. Required if log Kowis P 4.5 and in Tier B if log Kow P 3.
VMP. Required in Phase II Tier B if log Kowis P 4.
FA. Optional for phase IIB
HOCNF. Mandatory if log Kow > 3, but bivalve test can be conducted
alternatively.
Endocrine disruption
OECD 229 and OCSPP 890.1350: Fish short term
reproduction assay
REACH. Required in case of concern for endocrine disruption. (OECD, 2012b)
PPP. based on concern from mammalian and other data
TSCA, FIFRA, FFDCA: via endocrine disruptor screening program (US
EPA, 2011). EDSP tier 1 (US EPA, 2011)
80–96 (European
regulations) (US n.a.)
BioP Required in case of concern for endocrine disruption. (OECD, 2012b)
HMP. Conditional requirement.
VMP. Conditional requirement
OECD 230 Fish screening assay REACH. Required in case of concern for endocrine disruption. n.r. 80–96
PPP. Required in case of concern for endocrine disruption.
BioP. Required in case of concern for endocrine disruption.
HMP. Conditional requirement.
VMP. Conditional requirement






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































S. Scholz et al. / Regulatory Toxicology and Pharmacology 67 (2013) 506–530 511installation into each medium as well as identification of signifi-
cant effects of the emissions on the environment’’ (IED Directive).
The IED directive is closely linked to the Water Framework Direc-
tive (EU, 2000) that requires Member States to define reference
conditions for the good biological and chemical status of receiving
waters. Each Member State, however, has its own regulations and
environmental quality standards, including the need to present
ecotoxicological and environmental fate data. Some countries
(Denmark, Sweden, Ireland, Norway, France) require fish toxicity
testing to assess the effects of effluent discharge (Table 1; COHIBA,
2010;Embry et al., 2010; OSPAR, 2000). Fish testing for effluents
was also required in the UK, but has been derogated due to animal
welfare concerns (UK Environment Agency, 2006). According to the
UK Environment Agency guidance document, algae and inverte-
brates are generally considered more sensitive than fish and suffi-
cient to estimate effluent toxicity (UK Environment Agency, 2006).
Fish tests are only required if there is a defined fishery at risk from
acute effluent toxicity in the immediate vicinity of the discharge
point. Germany has replaced previous acute fish toxicity testing
for effluents by a standardized 48 h waste water test with zebrafish
(Danio rerio) embryos (ISO 15088, 2007). However, in the USA and
in Canada use of fish tests plays a more central role in effluent test-
ing as underlined by the high number of organisms used (see
Section 3).3. Number of animals used and status of acceptance of
alternative approaches
3.1. Statistics on animal numbers
On a tri-annual basis, the EU reports the number of animals
used for experimental and other scientific purposes in its Member
States. For the latest report available (EU, 2010c), summarising the
numbers for the year 2008 of 27 Member States, about 12 million
animals (vertebrates) were recorded. From this total, 1.9 million
were fish, amphibians or birds, which comprise those vertebrates
generally used in environmental hazard and risk assessment.
About 250,000 fish and birds were used for toxicological and other
safety evaluations with 140,000 animals tested for regulatory
requirements (Table 2). The actual number of vertebrates used
for environmental risk assessment might be higher, since animal
testing in other areas, such as basic research, product development
etc. may also relate to toxicological investigations. Furthermore, it
is difficult to precisely calculate the number of animals used in the
context of various regulations for environmental risk assessment,
since the EU does not disclose fish, amphibians and birds used with
respect to specific endpoints and regulations. Acute toxicity testing
is mandatory in most regulations while chronic toxicity testing and
BCF estimation is conditionally triggered by physico-chemical
properties, exposure routes and/or tonnage levels (Table 1). How-
ever, for the implementation of REACH due to the higher number
of animals needed per compound, chronic fish toxicity testing
has been estimated to contribute to the majority of vertebrates
needed for environmental hazard assessment in Europe (van der
Jagt et al., 2004).
Finally, the fact that between 3 and 6 million fish per year are
currently being used for whole effluent testing in the United
States33 and about 100,000 fish for regulatory testing of products
for the protection of humans, animals, or the environment in Canada
(CCAC, 2012) emphasises the pronounced need for alternative
methods on a global scale.33 The estimation is based on summarising information on types of tests done, their
frequency, number of reports for effluent studies for US states where this information
is available and an extrapolation to capture the entire US. Courtesy of S. Belanger.
Table 2
Number of experimental animals in the European Union reported for 2008 and proportion of fish, amphibian and birds used for regulatory toxicological and other safety
evaluations. Since fish, amphibians and birds are not used for assessment of human health, the number of animals used for safety evaluations in a regulatory context can be
associated to environmental risk assessment. Data were obtained from the European Union report on statistics of animal use for 2008 (EU, 2010c).
Total number of vertebrates: 12,001,022
Thereof used. . . . . .in any type of experiment (total) . . .in toxicity and safety analysis . . .for regulatory requirements
– Birds 764,111 53,128 50,603
– Amphibians 61,789 291 179
– Fish 1087,155 194,226 90,583
Total number of birds, amphibians and fish 1,913,055 247,645 141,365
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assessment, for assessment of hazards from diets and drinking
water, and for secondary poisoning (see Section 2.). However, the
EU statistics do not disclose the number of mammals that have
been used specifically for environmental hazard assessment. Fur-
thermore, mammals are only used in higher tier assessment when
there is specific concern for environmental risk. It is common to
use data from e.g. studies, which have already been performed
for human hazard assessment. Therefore, the actual number of
mammals specifically used for environmental hazard and risk
assessment is low compared to fish and birds.
3.2. Status of acceptance of alternative approaches focussing on
REACH
The REACH regulation states that ‘‘every effort must be made so
that testing chemicals on animals is a last resort – when there is no
other scientifically reliable way of showing the impact on humans
or the environment’’ (EU, 2006). Nonetheless some estimations
indicated that REACH may lead to a dramatic increase in the num-
ber of experimental animals used for risk assessment (Hartung and
Rovida, 2009). The recent report of ECHA (see Box 1 on REACH reg-
ulation statistics for details with respect to animal tests in environ-
mental risk assessment), however, indicates that alternative
approaches are frequently referenced in the registration process
of phase-in substances34 (ECHA, 2011;Spielmann et al., 2011). At
least in the initial registration phase, the applicants (registrants)
made extensive use of data sharing, which is one of the key mecha-
nisms anticipated to avoid unnecessary animal testing. Furthermore,
registrants made use of existing studies or non-test methods to pre-
dict properties of substances instead of experimental testing. The
following non-testing approaches were cited: (1) use of information
on similar substance (grouping and read-across); (2) information
combined from various sources (weight-of-evidence); (3) studies
using cells, tissues or organs (in vitro); (4) computer modelling
((Q) SAR, structural alerts etc.).
These data already indicate that there is a clear preference for
alternative or non-testing approaches (see Box 1 on REACH regula-
tion statistics). However, at present no data are available to dimen-
sion the extent to which ECHA has required additional animal
testing for situations that registration dossiers have made use of
hazard assessment based on alternative methods (ECHA, 2011).
Furthermore, in some cases, particularly for acute fish toxicity test-
ing, mainly data from animal studies (75%) were submitted for the
registrations. This may be due to the fact that such experimental
data were already available for high tonnage substances. Whether
these were derived from existing or new studies conducted for the34 Existing compounds (EINECS repository, esis.jrc.ec.europa.eu.), compounds pro-
duced or imported in the EU but not placed on the market within 15 years before the
entry into force of REACH, as well as compounds initially classified as polymers but
that do not meet the definition of polymers as set out in REACH are summarised as
‘‘phase-in compounds’’.purpose of REACH is unclear. It might be possible to avoid or re-
duce testing for future registrations by encouraging registrants to
use alternative approaches in the initial phase of dossier formation.
Due to a lack of experience by industry and regulators, it is, how-
ever, difficult to quickly arrive at an agreement on the ultimate
acceptance of results by scientists, industry and regulators. This
applies particularly for alternative experimental test systems, the
development of which may take many years to complete, while
new read-across and weight-of evidence cases and even some
(Q) SARs can be developed within the timeframes imposed by leg-
islation. The 2013 and 2018 REACH registration deadlines for lower
tonnage substances will provide further insight into the use of
alternative approaches.
Besides existing guidance (echa.europa.eu/web/guest/practi-
cal-guides) on how to report read-across, weight-of evidence
and (Q) SAR, documents from a recent ECHA/Cefic-LRI workshop
on read-across approaches inform about an envisaged read-
across assessment framework as a possible instrument for
streamlining information and documentation needs. The goal is
to overcome the current problems associated with the fact that
so far, it appears to be unclear when a given read-across ap-
proach is considered sufficient for regulatory acceptance, ‘‘and
how the remaining uncertainty should be dealt with’’ (ECHA,
2012). ECHA is expecting that outcomes of compliance checks
will allow a better understanding of the reliability of animal
and non-animal test methods used by registrants and hence im-
prove guidance on when alternative approaches are acceptable
(ECHA, 2011).
While the case-by-case registration process considers the use
of alternative or non-testing approaches, there are as of yet only
a few validated schemes for the use of alternative approaches to
predict effects for environmental risk assessment. The lack of val-
idated methods available as OECD test guidelines or guidance
documents (with the exception of the OECD guidance document
126 on the Threshold Approach for Acute Fish Toxicity and the re-
cently approved TG 236 for the Fish Embryo Acute Toxicity Test;
OECD, 2010, 2013) is probably one of the main reasons. An
important nuance of the REACH guidance, however, is that an
alternative does not need to be validated in the classic sense,
including e.g. a properly designed ring test, but only needs to
be ‘‘scientifically justified and supported’’, leaving open the possi-
bility that methods not yet fully validated in the formal sense can
be used (ECHA, 2008a). Explicitly this is stated in REACH, which
requires (Q) SAR-models to be valid, not necessarily validated.
Again, in practice, there is a lack of confidence within industry
and regulators about this issue. As a result, to avoid uncertainties
regarding the acceptability of their dossiers, industry has been
reluctant to use alternatives. This may change in the 2013 and
2018 registrations, but to achieve the increased use of alternative
approaches by the registrants, the availability of validated ap-
proaches (e.g. similar to the skin irritation/corrosion or eye
irritation in vitro tests used for human risk assessment) is a
requirement.
Fig. 1. Relative proportions of data sources to fulfil information requirements on environmental risk assessment endpoints for phase-in substances produced at P 1000 t/a
(1453 substances). The relative proportions were estimated on the substance levels, i.e. the percentage of compounds for which data from the appropriate source have been
used. Reproduced from (ECHA, 2011) Source: European Chemicals Agency, http://echa.europa.eu/ (ECHA, 2011).
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In June 2011, the European Chemicals Agency (ECHA) has
released the first report on the use of alternatives to testing
on animals for the REACH regulation (ECHA, 2011). ECHA
analysed the registration dossiers for high tonnage sub-
stances (>1000 t/a) submitted between 1 June 2008 and 28
February 2011 and also included information of on-going
REACH dossier evaluations. Data from 1504 REACH dossiers
covering phase-in substances were analysed for the percent-
age of registered substance, for which the registrants used
alternative approaches. For vertebrate testing in relation to
environmental risk assessment, the endpoints covered in-
cluded bioaccumulation (fish), short- and long-term toxicity
to fish as well as long-term toxicity to birds. With the excep-
tion of acute fish toxicity testing, alternative methods (testing
and non-testing approaches; Fig. 1) provided the ecotoxico-
logical information for more than 75% of the registered
substances.4. Alternative approaches
The 3R principles – replacement, reduction and refinement of
animal tests (Russell and Burch, 1959) – can be met by various
testing and non-testing approaches as described in more detail be-
low. Such approaches address the design and statistics of animal
tests or the replacement by alternative experimental and non-test-
ing methods. Non-testing approaches make use of scenarios for
exposure-based waiving, read-across, grouping and QSAR. Decision
trees in non-testing approaches provide a framework to obtain the
appropriate biological hazard information without animal testing
and require animal test-based methods only as a last resort.
In this context, a major step forward has been the introduction
of integrated testing strategies (ITS) as an operational means to
accomplish the 3Rs at least partly and on a short-term basis (e.g.
Hartung et al., 2013b;Grindon et al., 2006). The ITS approach for
a certain endpoint takes into account results from several alterna-
tive methods, and exploits their combined information content. To
this end, 3R-oriented methods – potentially relevant as ITS compo-
nents – include alternative experimental methods (chemoassays,35
in vitro/embryo assays) modifications of existing animal testing
schemes (Threshold Approach, Sequential testing, see Section 5.1)
and non-test methods (read-across, structural alerts, (Q) SARs, expo-
sure-based waiving, see Section 4.2). Appropriate ITS methods and35 Chemoassays measure the reacivity of a chemical to cellular molecules, such as
glutathion or DNA. Model substrates may be used as surrogates for native cellular
macromolecules.guidance have been developed for both human and environmental
hazard assessment (OSIRIS, 2011; Buist et al., 2013; Rorije et al.,
2013; Tluczkiewicz et al., 2013; Grindon et al., 2006; ECETOC,
2007; ECHA, 2008b).
4.1. Revision of test designs and risk assessment schemes
Even without available alternative methods, there would be
scope for a reduction of animal tests via modification of risk assess-
ment schemes or experimental test designs. For instance, whether
a benchmark dose/concentration or NOEC (No Observed Effect
Concentration)/LOEC (Lowest Observed Effect Concentration) ap-
proach is preferred over a threshold (see Section 5.1) or categorisa-
tion approach in risk assessment can have a significant impact on
the number of test animals. Many regulations require the classifi-
cation of toxicity according to the United Nations Global Harmoni-
sation System (GHS; UN, 2011). In Europe, this categorisation is
required by the CLP regulation (EU, 2009c), which is closely
interlinked to substance-type regulations on industrial chemicals,
biocides and plant protection products. Principally, the CLP regula-
tion could rely on limit tests, i.e. tests at predefined concentration
(s) which are already routinely applied in human risk assessment
for acute toxicity and require a reduced number of animals (Seidle
et al., 2010). For environmental risk assessment, however, recent
European guidance documents suggest provision of benchmark
concentrations or NOEC/LOEC values (EU, 2008b). The limit test
is already applied for acute fish toxicity at high exposure concen-
tration. I.e. an LC50 > 100 mg is considered as not toxic and no
classification or determination of benchmark concentrations,
respectively, is required above this level (OECD, 1992). However,
particularly biologically active compounds as often found among
PPPs and biocides fall short of this limit.
A categorisation approach would not need full concentration–
response data. I.e. it would principally require the testing of a lim-
ited number of concentrations offering the potential to reduce the
number of test animals. However, the regression-based benchmark
approach is often preferred and considered also advantageous over
the determination of NOEC/LOEC (Sand et al., 2006). Regression-
based modelling of effect concentrations is less affected by sample
size and data variability and more adequately describes the con-
centration–response relationship of a compound (Jager, 2012;
Landis and Chapman, 2011). It is therefore not surprising that the
development of alternative tests commonly deploys a regression-
based approach. This regression-based approach has also been ap-
proved by the OECD Working Group of National Co-ordinators in
2013 for a revised guideline of the FELS (Fish Early Life-Stage) test
(OECD 210). Motivation for this change was driven by an analysis
of OECD 210 studies by Oris et al. (2012) demonstrating that a
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studies used a minimum of 4 replicates per treatment (not the
minimum 2 as in the older guideline). Hence, the revision of the
FELS has led to an increase in the required number of animals
(from 60 to 80 fish per treatment as a minimum). However, a
regression/benchmark approach may not per se require an increase
in animal test numbers as this may be compensated by a reduced
number of animals per group compared to a group-wise statistics.
Nevertheless, even in case of an increase in animal test numbers,
the higher statistical power may facilitate more reliable correlation
with alternative methods. While we aim to reduce animal use in
the long term, it is also equally important to avoid ineffective use
of the animals in tests already used for environmental decision-
making, since these animals may simply be wasted if poor or
unsupportable conclusions are derived.
The number of test animals could also be reduced significantly
by application of the ‘Threshold of Toxicological Concern’ concept.
This concept was initially developed as a means to predict safe lev-
els of food additives for human consumption (U.S. FDA, 1993) and
has since been expanded to address a wide variety of human health
endpoints including carcinogenicity, teratogenicity, and reproduc-
tive toxicity (Kroes et al., 2005;Kroes et al., 2004). The TTC has been
applied in human health risk assessment by various regulatory
bodies in the US and Europe (for review see Hennes, 2012). The
concept aims at establishing a threshold level of exposure of no
concern for chemicals with little or no data based on the compar-
ison of the distribution of effect concentrations of chemicals for
which there is data. Central to this paradigm is the waiving of tests
in cases that exposure does not exceeds the threshold. Compounds
of certain structural characteristics known to exhibit low effect
concentrations may be exempted from the application of the
‘Threshold of Toxicological Concern’ concept. The TTC approach re-
lies on the availability of sufficiently large dataset for a particular
chemical structure series or mode of action. For environmental
endpoints, use of a TTC has been substantially less, however at-
tempts have been made (de Wolf et al., 2005; Gross et al., 2010;
Williams et al., 2011) providing the groundwork for future
investigations.
A critical review of global data requirements may also be useful
to identify potentially redundant requirements for testing and to
ensure greater international harmonisation. For example, a recent
survey of European crop protection companies indicates that
chronic fish toxicity testing of formulated PPPs (plant protection
products) – a potential requirement under EU legislation – is
rarely, if ever scientifically justified, as chronic exposure to the for-
mulation per se rarely occurs in the environment (Creton et al.,
2010). For bird testing, there are a number of international varia-
tions in terms of preferences for the use of particular species or
protocols, leading to a number of tests on the same endpoint being
conducted for one substance. It has not yet been critically analysed
whether this partial redundancy by testing in multiple species is
needed and whether a harmonisation in protocols and species
would lead to a loss of information and safety with respect to
the prediction of potential environmental hazards. Identifying
and eliminating unnecessary requirements (e.g. international vari-
ations for test species preferences) to conduct in vivo testing, and
improved international harmonisation could make a major contri-
bution to the reduction of animal use. However, implementing
such changes requires a scientifically sound base and close collab-
oration of international regulators.4.2. Non-testing approaches
Various non-testing approaches have been developed to replace
the use of animals in toxicological testing and to fill data gaps.These approaches include (Q) SARs, structural alerts, grouping
and read-across, the use of weight of evidence and data waiving.
(Quantitative) structure–activity relationships (QSARs) relate
molecular properties of a compound to a measure of a particular
activity, for example acute toxicity. The development of (Q) SARs
requires toxicological data (e.g. from databases or directly from
experimental data sets) that form the basis for developing predic-
tive models). Over the past three decades, numerous models have
been developed to predict physico-chemical properties that in turn
may serve to assess acute toxicity towards fish or birds, bioaccu-
mulation and other endpoints (Schüürmann et al., 2007). The most
commonly used QSARs for environmental effects predict narcosis-
level (baseline, non-polar narcotic) toxicity. Several computerised
tools assist with the application of QSARs to predict environmental
toxicity and bioconcentration, including VEGA (http://www.vega-
qsar.eu), Petrotox (http://www.concawe.be), Petrorisk (http://
www.concawe.be), CEFIC LRI Tool box (http://www.cefic-lri.org/
lri-toolbox), MultiCASE (http://www.multicase.com), TOPKAT
(accelrys.com/mini/toxicology/predictive-functionality.html) ECO-
SAR (as part of EPISuite http://www.epa.gov/opptintr/exposure/
pubs/episuite.htm), ChemProp (ChemProp, 2012;Schüürmann
et al., 1997), PBT Profiler (US EPA, 2005), Toxtree (http://source-
forge.net/projects/toxtree/) and many others (see http://www.
antares-life.eu for a compilation of available QSAR and other in
silico models). With the financial support by the EU, the OECD
has developed the OECD QSAR Toolbox, which is currently avail-
able as Version 3.1. (www.qsartoolbox.org) together with appro-
priate guidance. By analysis of the chemical classes represented
among the more than 100,000 EINECS (European Inventory of
Existing Commercial chemical Substances) substances, it was esti-
mated that existing (Q) SARs were covering already about 57% of
the EINECS compounds highlighting the relevance in safety assess-
ment (Zvinavashe et al., 2009). It must be noted that QSARs only
allow for the prediction of the toxicity of a single compound whilst
regulations, on e.g. pesticides and biocidal products, may request
the assessment of formulations. In order to predict the effects of
variable compositions and formulations, appropriate mixture tox-
icity concepts also have to be included. Concentration Addition
has been shown to provide a reasonable approximation for mix-
tures and could be applied in combination with QSARs if there is
no indication of – generally rarely observed – synergism or antag-
onism (Kortenkamp et al., 2009).
Structural alerts: Originally introduced for categorical end-
points from human toxicology such as mutagenicity and carcin-
ogenicity, structural alerts may also be used for the predictive
discrimination between narcosis-level and excess toxicity to-
wards aquatic organisms (Von der Ohe et al., 2005). Their deri-
vation may result from a statistical analysis of existing toxicity
data with the aim to relate the occurrence of excess toxicity to
certain structural features, and through targeted in chemico or
in vitro investigations of compound classes known for their gen-
eral potential to exert specific, e.g. reactive, modes of toxicolog-
ical action (Böhme et al., 2010; Blaschke et al., 2011; Schramm
et al., 2011). While the structural alert approach does not yield
a quantitative estimate of the LC50 or EC50 value, it provides
guidance about whether or not a narcosis-level QSAR is expected
to be applicable, and thus appears particularly useful as an in sil-
ico tool in the ITS context. Given the high level of confidence of
existing narcosis-level QSARs for different aquatic species, struc-
tural alert schemes – if applied within their application domains
– may contribute significantly to decreasing animal testing, sup-
porting the identification of cases where a narcosis-level QSAR
prediction can be considered confident.
Grouping-based read-across: Another in silico methodology is to
group ‘‘similar’’ chemicals and perform read-across, i.e. interpolate
the activity quantitatively through a trend analysis from a refer-
36 Endpoint study records (ESRs) summarise all endpoints reported in the dossiers.
For each endpoint, more than one ESR per dossier may have been submitted.
37 Toxicogenomics is defined here as profiling of changes in the transcriptome,
proteome and metabolome.
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able. Grouping or category formation alone may also assist in
selecting and developing appropriate QSARs or may be useful for
identifying prevalent mechanisms of action (OECD, 2007b; ECHA,
2010c; Carmichael et al., 2011). In this context, chemical similarity
is a key issue, and may concern physico-chemical properties gov-
erning bioavailability, structural features, modes or mechanisms
of toxicological action, and routes of metabolic activation or detox-
ification. Accordingly, grouping may become a complicated exer-
cise (Blackburn et al., 2011), and activities to incorporate
schemes for the similarity assessment by expert systems are on-
going within the OECD. Software that will assist in the grouping
of compounds and read-across prediction of compound properties
includes the OECD EQSAR Toolbox (http://www.qsartoolbox.org),
ToxTree (toxtree.sourceforge.net), AMBIT (ambit.sourceforge.net/
), and the OSIRIS edition of ChemProp (ChemProp, 2012).
Analogue-based read-across: In case only one or few sufficiently
similar compounds can be identified, the resultant reference set is
too small for performing a local trend analysis. Nevertheless, the
analogue data for the endpoint of interest still provide an expecta-
tion basis for the respective value of the target compound, and thus
can be used at least for a qualitative interpolation. Recently, an
algorithm employing so-called atom-centred fragments (ACFs)
used as an efficient general-purpose measure of structural similar-
ity has been developed. This algorithm allows one to exploit data
from only few analogues for predicting quantitative endpoints
such as the acute toxicity towards fish (Schüürmann et al., 2011).
This methodology is now fully automated (ChemProp, 2012), and
can also be used to complement respective QSAR predictions as a
basis for more elaborated consensus modelling and weight-of-evi-
dence (WoE) approaches.
Weight-of-evidence (WoE) is an approach that involves the
assessment of the relative weight of different pieces of available
information that have been retrieved and gathered in previous
investigations (Balls et al., 2006). To this end, a value is assigned
to each piece of information using either an objective method
(formalised procedure) or by expert judgement. The weight is
influenced by factors such as the data quality, consistency of re-
sults, nature and severity of effects, relevance, etc. To build a
weight-
of-evidence case, it is recommended to use information from all
possible sources, including published literature, read-across from
chemical analogues/homologues, QSAR, existing in vivo and
in vitro studies, epidemiological data etc. (ECHA, 2010a), which
are in line with the above-outlined ITS approach. In case of con-
sensus results from different (preferably alternative) methods for
a given target compound and endpoint of interest, a question is
how to convert the individual method-specific levels of confi-
dence (or uncertainty) to joint confidence (or uncertainty) for a
consensus outcome, and what would be a statistically sound
way to deal with conflicting results. Here, Bayesian statistics of-
fer a solution towards a quantitative weight of evidence as illus-
trated recently with an ITS approach for skin sensitization (Rorije
et al., 2013) that could be extended to endpoints relevant for
environmental hazard assessment.
Data waiving: The EU REACH legislation provides the possibility
to adapt and waive the standard testing requirements for several
endpoints on the basis of a number of rules that aim to avoid
unnecessary testing (ECHA, 2010b). Adaptation means the use of
non-standard methods (e.g. QSAR, grouping and read-across) for
fulfilling the information requirements, while waiving means that
the submission of the standard information for the particular end-
point is considered scientifically unnecessary, technically not pos-
sible, or not necessary based on low expected environmental
exposure concentrations in a specific case (ECHA, 2011). For envi-
ronmental hazard assessment in REACH, waiving of testing hasbeen proposed for none of the endpoint study records36 (ESRs)
for bioaccumulation and in only a very low number of ESRs for acute
fish toxicity (1.8%) in the dossiers registered as of 28 February 2011.
For long-term fish toxicity, waiving was proposed by about 34% of
the ESRs. No information is available on the actual number of accep-
tance of waiving (ECHA, 2011).
A specific example of a non-testing approach is the application
of acute-to-chronic ratios (acute-to-chronic ratios). The prediction
of ACRs represents a possible approach to identify compounds
likely to induce chronic toxicity (see Section 5.2 for details). They
are implemented for example in the Petrotox chronic toxicity pre-
diction tool (Redman et al., 2012).
A major breakthrough in non-testing approaches can be ex-
pected from the determination of the mechanism of action and
its propagation to apical endpoints (e.g. through advancement of
toxicogenomic methods, pathway analysis, and formation of Ad-
verse Outcome Pathways (AOPs, see Section 6.1). Understanding
the mechanisms is a pre-requisite for appropriate grouping of
chemicals and QSAR development. Structural alerts could be linked
to such mechanisms and allow classifying compounds with poten-
tial specific effects, such as receptor-mediated toxicity.
Application of in silico models require a clear definition of their
application domain, which is often lacking (Worth et al., 2007;
Netzeva et al., 2005; Hewitt and Ellison, 2010). An application do-
main may consist of several components such as physico-chemical
space (bioavailability), structural space (sub-structural features),
descriptor space (QSAR model parameters), MoA space (prevalent
modes of action), and metabolic space (biotransformation profile)
(Dimitrov et al., 2005). In the context of aquatic toxicity and bioac-
cumulation, consideration of basic physico-chemical properties
such as molecular weight, hydrophobicity (logKow) and water sol-
ubility, augmented by structural characteristics such as through
the ACF approach (Kühne et al., 2009), would represent minimal
criteria to describe the applicability domain, keeping in mind that
ACFs may partly capture information on modes of action and the
disposition for metabolic activation and detoxification. However,
detailed accounts of MoAs and of the metabolic profile are crucial
in improving both the application domain assessment and the pre-
diction capability of in silico models.
For QSAR models, a major drawback is also the current limitation
of a mechanistically sound quantification of reactive and other spe-
cific MoA to aquatic toxicity. While there is progress regarding the
electrophilic class of Michael acceptors (Schwöbel et al., 2010;Mul-
liner et al., 2011), the associated QSAR models are not applicable
across different compound classes, making their application domain
correspondingly small. Regarding reactive toxicity, a way forward
appears to expand research into in chemico and in silico approaches
for profiling and parameterizing chemical reactivity.
Key issues in the development and application of (Q) SARs are
e.g. the integration of data from various sources, the validation of
in silico models for toxic effects, integration of confidential data,
transparency of models and the need to establish an open standard
to promote interoperability and further development and applica-
tion (Hardy et al., 2010). These issues have been addressed by the
EU-funded project ‘‘OpenTox’’ (http://www.opentox.org) which
developed an Open Source- and Open Standards-based predictive
toxicology framework. Underlying these developments is the crea-
tion of a new open standard: the OpenTox Application Program-
ming Interface. For example, OpenTox has been extended to
support the infrastructure development of ToxBank supporting
the integration of in vitro, toxicogenomics37 and in silico evidence
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develop replacement methods in repeated dose toxicity (Kohonen
et al., 2013). Similarly the OpenTox approach could be applied to
the sector of environmental hazard assessment.
The OECD has already developed guidelines for (Q) SAR model
development to help increase their acceptability for regulatory
purposes (Zvinavashe et al., 2008). These guidelines propose that
(Q) SAR models should be associated with (i) a defined end point,
(ii) an unambiguous algorithm, (iii) a defined domain of applicabil-
ity, (iv) appropriate measures of goodness-of-fit, robustness, and
predictivity, and (v) a mechanistic interpretation. Specifically, the
following additional steps are needed to allow for a broader appli-
cation and acceptance of non-testing approaches in the implemen-
tation of the 3Rs in environmental risk assessment: (1) better use
of non-testing data such as mechanistic information and extrapo-
lations from existing human risk assessment data; (2) develop-
ment of improved QSAR-models for chronic toxicity; (3) better
definition of cut-offs, e.g. for solubility and volatility to aid
bioavailability modelling; (4) development of in silico models for
non-fish species, i.e. birds, and amphibians; (5) development of ex-
pert decision systems by combining outcomes of different data
sources (experimental vs. in silico vs. others), while focusing on
mechanistic knowledge-based approaches.4.3. Experimental model systems
There is a wide range of alternative test systems available, the
majority of them based on use of organ- and tissue-based or cellu-
lar in vitro systems and embryonic life stages (more details are pro-
vided in Section 5). Technologies to quantify responses of these
systems range from more traditional approaches, such as mortality
or viability analysis to increasingly sophisticated technologies,
such as reporter gene assays and toxicogenomics technologies,
which allow a system-wide view on various molecular and bio-
chemical levels (Schirmer et al., 2010). As such, alternative systems
have great potential to support the identification and elucidation of
modes/mechanisms of action, development of AOPs (Ankley et al.,
2010), and to serve in tiered testing approaches (e.g. Volz et al.,
2011; Murk et al., 2013). Moreover, many of these approaches
are amenable to high-throughput screening, finding utility in both
the private sector (for exclusion and prioritization testing), in reg-
ulatory testing and for field biomonitoring.
Ultimately, the alternative assays, be it alone or in combination,
need to be predictive of an outcome and corresponding effect con-
centrations of relevance to regulators (e.g., reproduction, develop-
ment, etc.). This should result in the development of models, which
are sufficiently predictive, or include them as an element in an
integrated testing strategy with enhanced predictive value
(Grindon et al., 2006). To this end, AOPs need to be constructed
and assays developed and validated (Hartung et al., 2004; Archer
et al., 1997; Hartung et al., 2013a) to specifically allow those links.
For mechanistic information, especially if related to highly con-
served genes and proteins, lessons learned from toxicogenomics
approaches in the human health area, e.g. the US EPA ToxCast pro-
gram (Kavlock et al., 2007; Collins et al., 2008; Sun et al., 2012),
should be evaluated for their potential for extrapolation to verte-
brate models used in environmental risk assessment.
To make full use of alternative test systems, all information
available should be used as part of a weight-of-evidence approach.
A challenge here is to use information among different domains. In
attempting to meet this challenge, it is important to incorporate
knowledge from mammalian toxicology studies, since these may
precede ecotoxicological hazard assessments and are often moreadvanced at the level of molecular, mechanistic research and in
the application of innovative approaches such as toxicogenomics.5. Replacement/reduction perspectives of endpoints relevant in
the regulatory framework
There are a limited number of endpoints relevant for environ-
mental hazard assessment and required by regulatory frameworks
(acute toxicity, chronic toxicity, endocrine disruption, bioconcen-
tration). Various approaches for replacement or reduction of ani-
mal tests addressing these endpoints have been suggested,
including refinement of test designs, non-testing approaches and
the use of alternative experimental test systems (see Section 4.).
At present, acute fish toxicity appears to represent the endpoint
where the predictive capacity of alternative approaches is most ad-
vanced and also validations have been successfully conducted.
Hence, this endpoint might be considered as a hallmark to imple-
ment alternative approaches in the regulatory framework for envi-
ronmental hazard and risk assessment. For acute bird toxicity, the
most recent guideline, OECD TG 223, can already be regarded as a
reduction and refinement compared to the older test guideline in
that the number of experimental animals has been reduced. The
relatively small number of animal tests conducted to assess acute
avian toxicity in the EU (required only for plant protection prod-
ucts or high tonnage levels for REACH) may explain the weak activ-
ities to identify replacement approaches. Therefore the focus on
alternative approaches to acute toxicity testing in this article will
be on fish. However, globally acute studies on birds are conducted
for every formulated plant protection product (PPP) registered in
certain countries (e.g. Brazil; IBAMA, 1996).
In the following sections, the present status and perspectives of
alternatives specific for a certain endpoint of regulatory relevance
are described. It should be noted that many of these endpoints,
irrespective of the regulatory scheme and substance type, share
similar limitations and challenges for improvement. This applies,
for instance, to the mechanistic understanding, consideration of
toxicokinetics and test design, which is more comprehensively dis-
cussed in Section 6.5.1. Alternatives to acute fish toxicity testing
The determination of acute toxicity of chemicals to fish accord-
ing to the OECD test guideline (TG) 203 is an integral component in
numerous national and international legislations (OECD, 1992).
OECD TG 203 has been nominated for revision on occasion of the
discussion of the OECD fish toxicity testing framework (OECD,
2012b). In fact, given the significant variability of acute fish toxicity
data found in databases and the open literature (Hrovat et al.,
2009), there appears to be a potential for improvement during
revision of this TG. In terms of the 3R principles replacement,
reduction and refinement, the Fish Embryo Acute Toxicity Test
(FET, OECD TG 236) with the zebrafish and genuine in vitro meth-
ods, such as fish cell culture tests, are under discussion and par-
tially already adopted. The latter is illustrated by the example of
current practices in whole effluent testing in Germany, where a
complete replacement of acute fish tests by the a 48 h FET has been
achieved for waste water regulations (Federal Law Gazette, 2005).
The FET shows an excellent correlation to re-evaluated acute fish
toxicity data (Lammer et al., 2009a) and an update by Belanger
et al. (2013) on the basis of a total of 220 chemicals covering a di-
verse group of chemicals has resulted in an almost perfect correla-
tion. Included in this compilation are data by Knöbel et al. (2012)
which show high correlation despite the explicit analysis of
chemicals with different modes of action and physico-chemical
S. Scholz et al. / Regulatory Toxicology and Pharmacology 67 (2013) 506–530 517properties. A few outliers, i.e. compounds which exhibit a
significant lower sensitivity in fish embryos – were observed in
this study and could be related to the metabolic capacity, high
hydrophobicity (logKow > 6) and/or mode of action demonstrating
some potential restriction in the applicability domain.
Cell cultures also have good promise as alternatives to acute
fish toxicity testing (Bols et al., 2005). A considerable number of
studies compared in vitro cytotoxicity of chemicals to fish cell lines
with the in vivo fish acute toxicity and confirmed the general
usability of fish cell lines (reviewed by Schirmer, 2006). However,
fish cell lines are not yet part of any regulation. A major stumbling
block thus far was an apparent underestimation of in vivo toxicity
by the fish cells by up to three orders of magnitude (Schirmer,
2006). Schirmer (2006) proposed several routes for advancing fish
cell line-based toxicity assays to overcome the aforementioned
hurdle: selecting cell lines derived from tissues reflective of the
chemical’s site and mode of action; increasing sensitivity of the
cellular response by modification of the culture environment to
more closely resemble the in vivo exposure; and by accounting
for the chemical fraction available to the cells. By realizing these
suggestions, Tanneberger et al. (2013) demonstrated a very good
correlation between the effective concentrations seen in a rainbow
trout (Oncorhynchus mykiss) gill cell line (RTgill-W1), and acute
lethal concentrations in fish (likewise close to the line of unity as
observed for FET vs. acute fish toxicity).
The systematic analysis of outliers in the correlation of cell lines
or embryos with acute fish toxicity should be used to limit the
applicability domain or develop measures for further improvement
of predicting acute fish toxicity. Such a systematic analysis could
identify specific mechanisms of action or physico-chemical proper-
ties for which acute toxicity in alternative test systems might be
under- or over-estimated. Minimising the potential for false nega-
tives would help improve the acceptability/validity of the alterna-
tive test systems.
Improved test designs such as in the Sequential Testing (Up/
Down Approach; Sunderam et al., 2004), the Threshold Approach
(OECD guidance document 126; OECD, 2010; Creton et al.,
2013a) or the Threshold (Step-Down) Approach (Jeram et al.,
2005;Hutchinson et al., 2003) can significantly reduce the number
of test animals. In Sequential Testing, only one fish is tested at a
time starting with an estimate of the expected LC50 concentration.
Subsequent tests are conducted with concentrations 1.3-fold above
or below the previous concentrations, depending on the outcome
of the previous test. Sequential testing is used already in bird acute
testing (OECD TG 233) but has not been included in acute fish tox-
icity guideline and guidance. While the traditional test design
(according to the OECD 203) requires at least 42 fish, Sequential
Testing only needs 6–7 fish. However, a major limitation to
Sequential Testing is the time it takes to derive an LC50 value, the
multiplication of preparing and analysing test solutions, and
potentially the increase in fish size (growth) during the sequential
testing. Therefore, it may not be used too frequently. In the Thresh-
old Approach the test design follows the requirements of the limit
test as described in the OECD 203 guideline. A test with fish is car-
ried out at a single concentration (threshold concentration) which
corresponds to the lowest of the EC50 concentrations obtained with
previous tests on algae and Daphnia. If fish mortality occurs at this
concentration, a full OECD 203 would be required. If no mortality is
observed, no further testing is required since fish are not the most
sensitive test species. A reduction of test animal numbers by 32 –
47% was estimated, depending on the database that was used for
the retrospective analysis (Hoeger et al., 2006;Creton et al.,
2013a). The basis for the Threshold Approach was the Threshold
(Step-Down) Approach, which uses fewer fish per concentration
and instead of a full OECD 203 test, 3.2-fold dilutions of the thresh-
old concentrations are tested step-wise as long as mortality is ob-served. This method was also evaluated with various existing acute
toxicity data sets, including agrochemicals, industrial chemicals,
and pharmaceuticals. Theoretical applications of the Threshold
(Step-Down) Approach would have result in a reduction of 54–
88% of the number of animal that would have been needed accord-
ing to the standard (OECD TG 203) acute fish toxicity test (Hoekzema
et al., 2006; Hoeger et al., 2006; Jeram et al., 2005;Hutchinson
et al., 2003). The different reduction levels in the Threshold
(Step-Down) Approach depend on the data source, whether con-
duction of a limit test was assumed for the acute fish toxicity test
according to OECD TG 203 or whether a group of control animals
was considered as necessary. However, the different variations of
the threshold approach may interfere with some risk assessment
schemes (e.g. for PPPs), that use varying assessment factors for fish
(100), Daphnia (100) and algae (10). Hence, in the case that algae
represent the most sensitive species, a lower risk could be pre-
dicted with the threshold approach if compared to a standard fish
acute toxicity test. Further, where higher tier refinements are used
for aquatic invertebrates or algae (e.g. mesocosm studies) the fish
toxicity endpoint may drive the risk assessment even though it is
not the most sensitive species. Therefore, in these cases careful
selection of the threshold is required to achieve animal reductions
and meet the requirements of the environmental risk assessment.
Both the Sequential Testing and the different Threshold
Approaches may also be combined with alternative test systems
such as fish cell lines or fish embryos (Rufli and Springer, 2011).
In silico methods such as QSARs, (computerised) read-across
variants (Schüürmann et al., 2011) and structural alert schemes
can also help to reduce testing for acute toxicity in fish. In the
ITS context, chemoassays such as non-animal experimental meth-
ods allow the determination of the toxicity-relevant reactivity
(Böhme et al., 2010). This can provide pertinent information about
the potential of a given compound for exerting reactive toxicity as
opposed to narcosis-level toxicity, the latter of which can be
predicted reasonably well from respective QSARs. A further 3R
opportunity is given by weight-of-evidence approaches or consen-
sus modelling, evaluating the combined information content from
several (non-test and experimental) ITS components in order to
compensate for individual method drawbacks (see Section 4).
5.2. Chronic toxicity
Due to improvements in environmental regulations, it has been
recognised that, with the exception of accidental spills, acute tox-
icity of contaminants is unlikely to occur, and continuous or re-
peated exposure to sublethal concentrations represents the
typical environmental situation. Consequently, the estimation of
chronic toxicity or long-term effects can be considered as one of
the most relevant categories in environmental hazard and risk
assessment resulting in requests for chronic toxicity testing in fish
and birds (and in case of plant protection products also mammals)
by various regulations (see Section 2, Table 1). Chronic toxicity
testing involves prolonged exposure to the test substance over a
significant portion of the organism’s lifecycle and may even in-
clude exposure over multiple generations.
However, due to the high costs and workload of such tests it is
common to conduct abbreviated tests, which may include highly
sensitive stages, such as the FELS test (OECD TG 210). Conse-
quently, the focus on alternatives to chronic fish toxicity testing
is presently with the FELS test. However, there is an increase in
the requirements for fish full lifecycle studies particularly follow-
ing extensive screening programs to identify chemicals which have
potential endocrine disrupting properties (e.g. the US-EPA’s Endo-
crine Disrupter Screening Program, (US EPA, 2011), see also 5.3 for
details). For chemicals where effects are observed in the screening
studies there is a need to investigate further in a higher-tier fish
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directives (CTGB, 2013; EU, 2009a) and US legislation (http://
www.epa.gov/oppefed1/ecorisk_ders/toera_analysis_eco.htm,
McElroy et al., 2011) require fish full life-cycle studies where cer-
tain criteria (toxicity, persistence and bioaccumulation) are met.
In the US, pesticide requirements include fish full life-cycle tests
in both freshwater and marine species depending on product and
proposed uses.
The development of alternatives to animal testing for chronic
toxicity has mainly been focussed on fish, probably due to fish rep-
resenting the largest group of experimental vertebrates in environ-
mental hazard assessment. Other species such as amphibians are
currently used only in specific applications e.g. chronic toxicity re-
lated to endocrine (thyroid hormone) disruption – and, hence,
development of alternative test systems have focussed mainly in
this area (Scholz et al., 2013) (see Section 5.3). Activities to develop
alternatives to avian chronic toxicity are rare. A few in vitro exper-
imental studies have, however, addressed potential chronic effects
such as immunotoxicity in lymphocytes and expression of specific
mRNAs in avian hepatocytes, neural cells or cardiomyocytes
(Ravindra et al., 2006; Jones and Kennedy, 2009; Vongphachan
et al., 2011;Crump et al., 2011). Some of these endpoints may be
useful to predict long-term effects, but these studies have neither
been explicitly designed nor been validated for this purpose. QSAR
models have not been reported for chronic toxicity in birds.
Two fundamentally different approaches have been proposed
for the reduction of chronic fish toxicity tests in environmental risk
assessment:
Acute to chronic ratios (ACRs): Prediction of ACRs, the quotient
of the effect concentrations of acute toxicity and chronic toxicity,
is anticipated to enhance the ability to identify compounds that
are likely to cause chronic effects (Kenaga, 1982;Raimondo et al.,
2007; Ahlers et al., 2006). In this approach the acute toxicity is
typically derived from a regression-based modelling, while for
chronic toxicity NOECs have been used. The principal assump-
tion is that compounds characterised by a high ACR (>10 or
>30 are used as thresholds) may exhibit specific physico-chemi-
cal characteristics, structural properties or modes of action and
that these specifically acting toxic compounds could be identi-
fied by analysing their characteristics. Specific action would be
needed to assess whether the concept is applicable for numerous
classes of compounds.
An ACR of 10 was proposed and applied for the extrapolation
from acute to chronic toxicity for mixtures, since this factor was
found to represent the average ratio of the LC50 of acute to the
NOEC for chronic toxicity (De Zwart, 2002;Van den Brink et al.,
2006). For non-specific, narcotic compounds, for example hydro-
carbons from petroleum, an empirical ACR prediction model based
on the target lipid model has been developed (McGrath and Di
Toro, 2009;Redman et al., 2012). The model is based on the critical
target lipid body burdens, considers low bioavailability of highly
hydrobphobic compounds (logKow > 6) and utilises a database de-
rived from acute and chronic effect concentrations of 55 organ-
isms. It was hypothesised that specifically acting compounds
would show a more pronounced time-dependence of toxicity than
narcotics. Application of the 4-MoA and 7-MoA classification
schemes of Verhaar et al. (1992) and Russom et al. (1997), respec-
tively, demonstrated that narcosis-level toxicity in the acute expo-
sure regime is often associated with low ACR values (Ahlers et al.,
2006). A further interesting result is that the highest ACR values
were found for compounds with log Kow values around 4 to 5 sug-
gesting that chronic toxicity is partially and particularly in case of
limited metabolism associated with bioconcentration. However,
for the application in a regulatory framework in order to predict
chronic toxicity, a reliable approach for the ACR assessment of
individual compounds including non-narcotics would be needed.This is illustrated by the comparison of acute and chronic toxicity
for a set of 32 new and existing industrial organic chemicals with
data validated by governmental authorities (Ahlers et al., 2006).
For these compounds, the median, 90th percentile and maximum
ACR was 10.5, 198.2 and 4250, respectively. Assuming a factor of
e.g. 100 as upper ACR level would not be protective at the 90% level
of confidence. The substantial variation in observed ACRs is likely
to reflect the fact that the prevalent MoA may vary with exposure
time, and that the extent of this variation also depends on the MoA
type.
Adverse Outcome Pathways (AOPs): Recent initiatives have pro-
posed making larger use of information from alternative methods
in a more mechanistically-assisted risk assessment approach (Volz
et al., 2011). This approach, which is also referred to as the AOP
concept (Ankley et al., 2010), aims to provide causal links between
chemical exposure, the molecular initiating event, specific key
events in the toxicity pathway and the adverse outcome at the
individual or population level. Identifying the molecular initiating
and/or key events characterising an AOP may allow prediction of
chronic toxicity. The AOP approach may not be an absolutely
new concept, but it is the first time that the principles have been
formalised and that regulators became aware of its perspectives
with regard to replacing animal tests (OECD, 2012e; Villeneuve
and Garcia-Reyero, 2011).
A limitation of alternatives for chronic toxicity testing is the
restricted ability to predict a variety of complex long-term ef-
fects in the whole organism from short-term testing. However,
since most if not all types of toxicity can be explained by an ini-
tial molecular interaction, the identification and quantification of
molecular interactions and their corresponding AOPs provide a
key to develop alternative assays for the prediction of long-term
effects. For instance, a comparison of the LOEC of FELS tests and
gene expression data in fish embryos has indicated a concentra-
tion-dependent differential expression of marker genes below
concentrations causing acute toxicity effects and close to LOECs
in the FELS test (Weil et al., 2009; Voelker et al., 2007). Likewise,
other studies have focused on the analysis of molecular end-
points in alternative test systems, i.e. fish embryos, primary
and permanent fish cells. The major challenge to use this molec-
ular information would be to link them mechanistically to AOPs
in order to provide a causal and quantitative (with respect to ef-
fect concentrations) link to apical endpoints. A tiered, mecha-
nism-based scheme focusing on molecular and cellular targets
linked to AOPs in fish cells or embryos has been proposed to re-
place or prioritize testing with the fish early life-stage test (Volz
et al., 2011). It is as yet not clear which type of sublethal, cellu-
lar endpoints or combinations thereof will provide a sufficient
predictive power for chronic effects or mechanism associated
with chronic toxicity, and further research is needed in this field.
Toxicogenomic approaches are likely to support the development
of AOPs provided that suitable markers for prediction of apical
endpoints emerge.
The prediction of chronic effects in non-target organism by
using human therapeutic data has been proposed as a way forward
to avoid and reduce the number of animals in environmental risk
assessment – particularly for pharmaceuticals given the availabil-
ity of human data (Schreiber et al., 2011; Huggett et al., 2003;
Scholz et al., 2010). Similarly, effect concentrations from mamma-
lian species obtained for the human risk assessment of industrial
chemicals, pesticides and biocides could be utilised. Invertebrate
tests could also provide useful information, although species dif-
ferences in sensitivity must be considered carefully. In order to de-
ploy mammalian or invertebrate information, a retrospective
analysis of existing data would allow a first estimate as to whether
this approach can be applied in principle. However, such an evalu-
ation has not been conducted so far.
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Endocrine disrupting chemicals (EDCs) can, according to the
WHO International Programme for Chemical Safety (IPCS), be
defined as ‘‘. . .exogenous substances that alter function(s) of the
endocrine system and consequently cause adverse health effects
in an intact organism, or its progeny, or (sub) populations’’ (UNEP,
2012). Concern over endocrine disruption by chemicals has led to
recent legislative changes in Europe (ec.europa.eu/environment/
endocrine/index_en.htm) and North America aimed at the identifi-
cation of potential endocrine mediated effects using screening
tools and the prediction of adverse effects using long-term ecotox-
icological tests (e.g., the US Endocrine Disruptor screening
program, http://www.epa.gov/scipoly/oscpendo/index.htm). At
the screening level, both mechanistic in vitro assays (e.g. recep-
tor-binding assays, reporter gene assays for estrogenic, androgenic
or thyroid hormone disrupting effects) and in vivo assays (e.g. fish
and amphibian screens, Table 1) are being performed. Higher tier
or confirmatory tests focus mainly on reproduction and develop-
ment in order to predict population-relevant effects and, hence,
represent the most animal-intensive tests used in environmental
risk assessment (e.g. fish full life-cycle and avian two-generation
tests). Alternative methods at the screening level are currently
available for a limited number of endpoints. These concern recep-
tor-binding affinity (including estrogen and androgen receptor
binding affinity, estrogen receptor transactivation, cell prolifera-
tion in vitro assays) and interference with steroidogenesis. The
intention, at least within Europe, is that alternative methods can
be used in combination with all other relevant information such
as pre-existing eco/toxicological data, QSARs and read-across to se-
lect subsequent in vivo assays (for example see Knacker et al.,
2010; Bars et al., 2012; Bars et al., 2011). Putative endocrine effects
need to be compared to systemic or other specific toxicity to esti-
mate whether these are truly endocrine-mediated or reflect sec-
ondary responses (e.g. Munn and Goumenou, 2013; Wheeler
et al., 2013). This is important with regard to the severe regulatory
consequences of endocrine disruption of a chemical under certain
parts of European legislation (e.g. removal from market or restric-
tions) and therefore, highlighting the importance to satisfy both
components of the WHO/IPCS definition by establishing causality
between adverse effects and an endocrine mode of action.
There is scope, however, within the currently available tools, to
reduce the overall use of animals in the identification and assess-
ment of endocrine disrupters in fish and amphibians. These include
(i) making good use of the information available from tests with
other vertebrates including mammals, (ii) the application of
in vitro approaches and working to enhance the number and power
of these methodologies, (iv) the use of invertebrate alternatives or
vertebrate embryos, (v) in silico approaches and (vi) refinement
and improvement of the current in vivo tests.5.3.1. Use of mammalian data
It is most likely that endocrine specific testing in ecotoxicolog-
ical species will be triggered by concerns from the mammalian tox-
icology database in combination with relevant in vitro studies
(where available). These in vitro assays, although of mammalian
origin, address basic molecular mechanisms and, hence, can be
considered as relevant to environmental species (e.g. Witters
et al., 2010; Freyberger et al., 2010). The combination of a
weight-of-evidence evaluation using peer-reviewed literature,
read-across information from structurally similar substances and
in vitro screening or in vivo mammalian data may provide sufficient
information to waive screening or definitive tests (required by reg-
ulation) typically conducted for environmental risk assessment.5.3.2. Use of in vitroapproaches
Hormone systems are very complex and include aspects such as
central regulation via the hypothalamus-pituitary-gonad or -thy-
roid-axis and hormone production. However, there are systematic
approaches to identify the biological relevance of known targets
for endocrine disruption. For mammalians, several test guidelines
(TGs) based on the use of cultured cells are now being developed
at the OECD for the detection of endocrine activity. Currently avail-
able are OECD TG 455 transcriptional activation assay for the
detection of estrogen agonists (OECD, 2009b) and OECD TG 456
steroidogenesis assay (OECD, 2009a). Also for thyroid hormone dis-
rupting chemicals a battery of in vitro tests that can replace in vivo
testing has been identified (Murk et al., 2013). This approach cur-
rently is being followed up by an OECD thyroid hormone scoping
working group. For fish and amphibians, at present no guidelines
for alternative assays are available. However, comparison of exist-
ing in vivo and in vitro data for fish and amphibians indicate a
correlation and partially similar sensitivity, particularly for com-
pounds of which the endocrine disrupting effects are mediated
by receptor binding (Scholz et al., 2013). There are concerns that
in vitro tests capture substances with endocrine activity, without
discrimination of their potency (Weltje et al., 2013). As more data
and greater experience is obtained with in vitro methodologies and
as responses are calibrated with in vivo tests, appropriate ‘cut-off’
thresholds for positive in vitro responses could be established.
For example, positive outcomes in receptor-binding assays are of-
ten identified only at unrealistically high exposure concentrations,
which are already cytotoxic (Scholz et al., 2013). Therefore, low
potency in relation to cytotoxicity at the in vitro level could be con-
sidered as a negative result and thus not be a priority for further
need of confirmatory in vivo tests. Such an approach would need
to be balanced with other limitations inherent to in vitro assays
such as limited metabolic activation (Beresford et al., 2000).
5.3.3. Use of invertebrates and embryos
Invertebrate species: The endocrine system of several inverte-
brate species shares similarities with vertebrate species. An exam-
ple are echinoderms such as sea urchins (Porte et al., 2006) that
also undergo a thyroid hormone-dependent metamorphosis. As-
says using echinoderms are able to identify thyroid hormone-dis-
rupting compounds (Anselmo et al., 2011;Anselmo, 2012). It is,
however, acknowledged that endocrine targets (e.g. estrogen
receptors) are not universally conserved across taxa (Gunnarsson
et al., 2008); thus, read-across between phylogenetically distant
species may be challenging.
Fish and amphibian embryos: Embryos may also prove useful as
alternatives for endocrine disruption testing. If the embryo test is
designed to tackle receptor interaction, primary target genes for
hormones can be investigated and particularly transgenic strains
could be useful to screen hormonal effects. Transgenic strains
responsive to estrogens (zebrafish cyp19a1b:GFP, e.g. Brion et al.,
2012) or thyroid hormone interaction (zebrafish TSH:eGFP and
tg:mCherry, Xenopus TH/bZIP:eGPF; Ji et al., 2012; Fini et al.,
2012; Opitz et al., 2012) represent appropriate examples. For the
Xenopus TH/bZip:eGFP construct, an OECD validation study has
already been initiated (OECD, 2012d). Moreover, compounds
interfering with thyroid hormone synthesis have been monitored
in fish embryos by analysing T3 hormone levels using an immuno-
chemical approach (Thienpont et al., 2011).
5.3.4. Refinements to in vivo approaches
Alternative test systems have only recently reached the point
where they are applied widely in regulatory testing and screening
schemes (e.g. the US-EPA’s Endocrine Disrupter Screening
Programme, http://www.epa.gov/endo). Consequently, there is at
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ties to improve the 3R aspects of these methods. However, already
the refinement of recent in vivo approaches offers the potential of
significant reduction of test animals.
Species choice. Typically, the OECD test guidelines for endo-
crine disruption testing are developed for at least the three stan-
dard fish test species (fathead minnow, medaka and zebrafish).
There are strong regional preferences and different biological
advantages to determine the choice of the species such as avail-
ability of secondary sex characters (e.g. medaka and fathead
minnow versus zebrafish), or body size making blood sampling
easier (e.g. fathead minnow). This species choice can affect the
number of animals required. For instance, a fish short-term
reproduction assay according to the US EPA guideline OCSPP
890.1350) with fathead minnow would use about 152 fish,
whereas a fish screening assay (OECD 230) test with zebrafish
would only use 80 fish (US EPA, 2009; OECD, 2012b). The cur-
rent practice of species and test choice should be analysed crit-
ically with respect to determine whether a particular species or
test gives higher confidence for environmental protection. If
there is no rationale for the use of a particular species, a reduc-
tion of the total number of animals used could be achieved by
mutual acceptance of the results of a particular (i.e. preferred)
species. Furthermore, using the same species for both screening
and definite tests could be advantageous, since the screen will
serve as a range finder for higher tier testing. For instance, for
fish screening tests there is a de facto preference for fathead
minnow, at least for substances that are globally assessed, due
to specification for the US-EPA endocrine disrupter screening
program (US EPA, 2011). In contrast, for higher tier fish full
life-cycle tests, medaka has emerged as the preferred species be-
cause of its size, shorter generation time and genotypic sex
markers enabling the same endpoints to be determined with
fewer individuals and with higher certainty than with other spe-
cies. This conflict has already been acknowledged as an issue by
the OECD fish toxicity testing framework (OECD, 2012b).
Standard long-term toxicity assays: Long-term toxicity tests are
already performed (typically OECD 210 fish early life-stage tests)
in the standard assessment of substances (e.g., to provide
chronic fish toxicity data for EU REACH registrations). It is recog-
nised that the relevance of this test could be enhanced by inclu-
sion of additional endpoints. For example, there is potential for
taking histopathological and/or tissues samples for biomarker
analysis, if there were any concerns (e.g. from structural alerts)
that the substance could possess endocrine disruption properties.
Clearly there would be animal welfare and cost benefit issues, if
multiple questions could be addressed without the need for
additional animal testing.
Duplication of endpoints: At the screening tiers, there are two
clearly defined key tests: the fish screening tests and the amphib-
ian metamorphosis assay which address different endocrine axes,
i.e. the hypothalamic–pituitary–gonadal and the hypothalamic–
pituitary–thyroid axis. However, at higher tier testing, there is
overlap of endpoints (e.g. sexual development) in the fish and
amphibian assays. Given the conserved nature of the vertebrate
endocrine system, there may be an opportunity to start with only
one higher tier test and only in case of non-conclusive results con-
sider a 2nd higher tier test to address any concerns identified at the
screening stage.
Numbers of generations: Currently, there is also a debate on the
number of generations required for higher tier studies such as the
fish full life-cycle test. There is no indication that there is a need for
addressing more than two and – similar as in the field of human
hazard assessment – extended 1-generation reproduction tests
could supersede multiple generation tests (Spielmann and Vogel,
2007;OECD, 2012c).5.3.5. Limitations and research needs of alternative approaches in
endocrine disruption
The regulatory consequences of a substance being considered
(identified or classified) an EDC are high, and, therefore, there is
significant pressure to provide definitive answers to address any
potential EDC concerns. Apart from general limitations of alterna-
tive test systems (see Section 6) sensitive target organs such as go-
nads are not addressed by cellular assays or are in a very early
stage of differentiation in fish and amphibian embryos. As a conse-
quence, the use of vertebrate higher tier tests is at present pre-
ferred also at the screening level. The US-EDSP will present a
unique and invaluable source of information to evaluate the per-
formance of the tier 1 in vitro tests and provide data to enable test
design optimisation to accommodate animal welfare consider-
ations. In fact, this is part of the intent of the US-EPA as it drives
forward to develop the next generation of assays as a part of its
EDSP 21 programme, placing greater emphasis on using computa-
tional or in silico models and molecular-based in vitro high-
throughput (HTP) assays to prioritise and screen chemicals (US
EPA, 2011). An intermediate solution might be that the in vitro test
battery is applied in combination with conventional approaches, to
reassure regulatory authorities (Scholz et al., 2013).
There is a clear need for a systematic approach as suggested
above to provide a battery of existing or desired in vitro assays
for biologically relevant endpoints of known mechanisms for EDCs.
For a number of known EDCs the responses of this battery of tests
should be compared to the already existing in vivo assays. The
comparison of predicted and determined in vivo effects will iden-
tify research gaps and needs, before a battery of test methods
can be advised for a tiered approach with triggers for labelling a
compound as an EDC with low or high concern. In case of the latter
the compound would be a candidate for further investigation.
Ultimately, practical experience during regulatory programmes
(e.g. US-EPA EDSP) will inform on the applicability domains and
constraints of such approaches and indicate areas for reduction
of animal use.
5.4. Bioaccumulation
Bioaccumulation is defined as the biological sequestering of
xenobiotics and/or their metabolites by uptake via food, water,
air, or sediment, such that the concentration in the organism is
greater than that in its surroundings or food. Bioaccumulation is
the result of absorption, distribution, metabolism, and excretion
processes within the organism. Since the United Nations Stock-
holm Convention on persistent organic pollutants (POPs) was
adopted in 2001, there has been significant activity concerning
the assessment of persistent, bioaccumulative, toxic (PBT) sub-
stances worldwide. Current regulations for industrial chemicals,
plant protection products, biocidal products and pharmaceuticals
require testing for the bioaccumulation potential by estimating a
bioconcentration factor (BCF) in aquatic organisms. The require-
ment for BCF estimation in legislation is driven by certain criteria,
such as production volumes and/or hydrophobicity (as described
by the chemical’s logKow). For example, the European REACH regu-
lation requires chemical substances produced above 100 tons/year
to be evaluated for their potential to bioaccumulate in the environ-
ment. This requirement is contingent upon the logKow being P3
(Table 1). In order to avoid unnecessary testing on animals, REACH
requests the use of existing information from standard and non-
standard methods, in vitro methods, in silico methods, read-across,
and weight-of-evidence in an integrated testing strategy for
assessing the bioaccumulative potential of a substance. Despite
this, a recent ECHA review (see Section 3, ECHA, 2011) reveals that
still 42% of the recently submitted REACH dossiers for chemicals
produced over 1000 tons/year (1500 chemicals) contained bioac-
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OECD, 2012f).
There is a clear need to develop alternative methods for evalu-
ating the bioconcentration of the thousands of chemicals that will
need to be assessed over the next few years, taking into account
integrated testing strategies and a tiered, weight-of-evidence ap-
proach. These alternatives may include enhancement of modeling
approaches, use of cellular or fish embryo test systems, refinement
of in vivo methods, solid phase microextraction (SPME) and poten-
tial combination of assays to address active transport and meta-
bolic processes. The use of SPME has been suggested as an
approach to ‘biomimic’ bioconcentration and has been recognised
by OSPAR (OSPAR, 2007) and under REACH (ECHA, 2008c) as a
technique which can give an initial estimate of bioaccumulation
potential of components of effluents and multi constituent
substances.
Currently, determination of the BCF is performed according to
the OECD TG 305 (OECD, 2012f). Overall, this method is time-
and cost-intensive, and the basic protocol requires a minimum
of 108 fish per chemical. The guideline was recently revised,
and major changes include the ability to test at a single concen-
tration, if it is anticipated that uptake is not likely to be concen-
tration-dependent. This has been demonstrated to be the case in
an analysis of 55 plant protection product active substances indi-
cating a good potential for reduction for pesticides (Creton et al.,
2013b). In addition, a ‘‘limit test’’ approach has also been incor-
porated, which requires a reduced number of sampling points (a
minimum of two samples taken during the depuration phase).
The BCF calculation is then based on deriving a kinetic BCF
(constants of uptake/depuration rate or k1/k2) rather than deter-
mining a steady-state BCF (Arnot and Gobas, 2006). This will
allow a significant reduction in the number of fish to be used
to determine the bioconcentration potential of a substance.
Finally, the revised methodology contains a test for dietary expo-
sure, which is proposed for certain groups of substances where
aqueous exposure is not suitable. This applies for high logKow
(>5.5) compounds.
The majority of current alternative, preliminary bioaccumula-
tion assessments rely on QSAR- and logKow-based estimates for
fish (Arnot and Gobas, 2006) such as the BCFBAF™ program from
the Estimation Program Interface (EPI) Suite (US EPA, 2013). These
models already consider (estimated) biotransformation rates (km).
However, for many chemicals, the existing models may not be va-
lid, outside of the applicability domain and/or do not account suf-
ficiently for the impact of ADME processes in the organism. There
is also ongoing work to integrate in vitro methods into QSAR mod-
els (e.g., isolated hepatocytes, subcellular fractions, and cell lines)
to measure the metabolism of chemicals and to use this informa-
tion as a key parameter in combination with existing models
(Cowan-Ellsberry et al., 2008;Johanning et al., 2001; Baron et al.,
2012;Nichols et al., 2006; Nichols et al., 2013). Nichols et al.
(2006, 2013) created a physiologically based toxicokinetic (PBTK)
model for fish, where in vivo metabolism rates are extrapolated
from intrinsic in vitro clearance rates. For the determination of
intrinsic clearance, fish liver S9 fractions or microsomes can be
used. These fractions are enriched in phase I metabolising enzymes
and some phase II conjugation enzymes (Weisbrod et al., 2009) and
mimic the hepatic in vivo metabolism. Furthermore, existing and
recently generated in vivo data are being analysed to incorporate
chemical dietary uptake efficiency into bioaccumulation estima-
tion models (Parkerton et al., 2012).
Quantification of internal doses may provide a key to calculate
BCFs in alternative test systems (such as embryos, larvae, or cell
culture). However, bioconcentration test designs require exposure
of cells and embryos to non-toxic, i.e. comparatively low chemical
concentrations. Chemical analysis of these concentrations withinsmall-scale systems is challenging due to the need to reliably
quantify low absolute chemical amounts, but is not impossible
(e.g. Kühnert et al., 2013;Broeders et al., 2013; Schirmer et al.,
1997). The use of radioactively labeled compounds can solve ana-
lytical determinations and also provides specificity for parent
compounds and transformation products if combined with appro-
priate analytical separation techniques such as HPLC. However,
this approach might be cost-prohibitive and not available to all
laboratories. Provided that exposure concentrations are not af-
fected by sorption or volatilisation of test compounds (e.g. by using
locked glass vials), BCFs may indirectly be calculated from the
reduction kinetic of exposure concentrations in the fish embryo
test (Schreiber et al., 2009). This approach was already proposed
for the estimation of BCFs using adult fish (Banerjee et al., 1984),
but was controversially discussed due to interference with trans-
formation processes (Parkerton et al., 2008). More recently, also
an analysis of hydrophobic compounds in zebrafish embryos indi-
cated that internal concentration time courses cannot reliably be
predicted from the decline of exposure concentrations (Kühnert
et al., 2013).
As there are still a number of areas of uncertainty related to the
alternative BCF assessments, the current practice of regulatory
authorities is to require in vivo data. The main reason being that
the risk of obtaining under-/overestimation of BCFs by using data
from alternative test systems is difficult to estimate. One of the
key issues with future acceptance of any alternative approach for
bioaccumulation/bioconcentration assessment will be how the
data are viewed by regulatory authorities to identify PBT com-
pounds (i.e. compounds with high persistence, bioaccumulation
and toxicity). For example, if an alternative approach indicates that
the bioconcentration potential of a substance is negligible, then it
may be considered unnecessary to perform a full fish bioconcentra-
tion study or simply the reduced (limit test) approach may be suf-
ficient. Similarly, if the substance is clearly bioaccumulative (B) or
very bioaccumulative (vB) (i.e. BCF >2000 or >5000), then it may
also not be necessary to perform a full fish bioconcentration test.
Similar to other endpoints and alternative approaches, research
has to be intensified to identify suitable tests/strategies or amend
existing methods with high capacity for successful validation and
regulatory acceptance.6. Common limitations, perspectives and research needs
Regardless of the endpoint to be predicted, there are limitations
and research needs common to most of the alternative approaches.
However, many of these limitations are also linked with promising
perspectives for future developments as described below.6.1. Mechanism-based approaches
The sequence of events from chemical structure through molec-
ular initiating events, cellular and organism responses to final ad-
verse effects – formalised in the adverse outcome pathway (AOP)
concept (Ankley et al., 2010) – provides the opportunity to identify
key events that could be targeted by alternative assays. An
example is given by the detailed formulation of the AOP for skin
sensitization in human hazard assessment (OECD, 2012a). Corre-
spondingly, AOPs have been proposed for environmental hazard
assessment, e.g. for chronic fish toxicity or endocrine disruption
(Volz et al., 2011; Kramer et al., 2011; Ankley et al., 2010;
Villeneuve et al., 2013). Although the AOP concept has been
acknowledged by many scientists, the development of alternative
tests will still require proof of concept and ultimately regulatory
acceptance of the AOP methodology. Parallel paths are being taken
in human safety (e.g., Tox21 by the USEPA; Risk21 under ILSI-HESI)
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being broadly supported by OECD. Recently, the Tox21 framework
was used to rapidly test for hazards associated with different oil
dispersant options in the oil spill in the Gulf of Mexico in the
summer of 2010 by (partially) mechanistic in vitro assay (Judson
et al., 2010). Environmental scientists should also take advantage
of these opportunities by developing environmental AOP concepts
and frameworks with established links between mechanistic and
apical endpoints relevant for regulatory decisions on the hazard
and risk assessment of chemicals (OECD, 2012e).
A detailed mechanistic understanding can also help to identify
potential limitation of alternative approaches, i.e. the identifica-
tion of the lack of representation of particular modes of action
and the ability to model them to the same extent in an alterna-
tive approach. This has been partially addressed, for instance for
the replacement of the fish acute toxicity test with the FET. An
analysis of fish embryo acute toxicity data by Knöbel et al.
(2012) and of fish gill cell line viability data by Tanneberger
et al. (2013) indicated that some outliers could be related to
the mechanism of action (see also Section 5.1). Appropriate mod-
ifications of the test setup were suggested to help overcome these
limitations but further research is required to establish these and
prove their effectiveness. Inclusion of MoA-targeted assays such
as investigation neurotoxicity by behavioural analyses (Kokel
et al., 2010; Selderslaghs et al., 2013), might improve the predic-
tive capacity.
Finally, mechanistic studies such as those conducted in the US-
EPA ToxCast program should also be evaluated to identify the
appropriate key events which can predict adverse effects on the
environment.
6.2. Bioavailability and stability of test concentrations
Limitations of alternative test systems can also be associated
with the exposure design. For instance, plastic multi-well plates
commonly used in cell- and embryo-based test systems may ad-
sorb lipophilic compounds (logKow P ca. 3). This can affect expo-
sure concentrations, particularly with chemicals that are poorly
water soluble. Volatilisation from exposure vessels can also con-
tribute to significant losses of test compounds (Riedl and Alten-
burger, 2007; Schreiber et al., 2008; Tanneberger et al., 2010). In
cell culture systems, binding to medium ingredients (serum pro-
teins) may additionally reduce the bioavailable concentration of
the compound (Kramer et al., 2009; Schirmer et al., 1997). Test set-
ups that ensure stable exposure concentrations over the test dura-
tion are required to ensure that difficult-to-handle compounds, i.e.
those with high volatility or hydrophobicity can be properly as-
sessed. Potential test set ups may include flow-through designs
(Lammer et al., 2009b) or passive dosing (Kramer et al., 2010;
Smith et al., 2010; Smith et al., 2009;Brown et al., 2001). In the pas-
sive dosing approach, the chemical partitions into the medium
from a biologically inert polymer previously loaded with the chem-
ical. This technique enables maintenance of a stable exposure con-
centration and has been applied for a range of biological tests
where exposures were performed in plastic multi-well plates.
However, this technique is currently very labour-intensive, and
no standard operation procedures are available. Alternatively, the
compound loss through sorption and volatilization can be cor-
rected through an empirical relationship with hydrophobicity
and Henry’s law constant (Schramm et al., 2011), provided an
appropriate model can be derived for the in vitro system of interest
and with a reasonable work load.
Until relatively recently, exposure concentrations were rarely
analysed in cell culture or embryo tests and hence, effect concen-
trations were calculated based on nominal (intended) concentra-
tions. However, analytical verification of exposure concentrationis already required and routinely applied for in vivo tests and has
been implemented in the recently approved TG 236 for the Fish
Embryo Acute Toxicity Test (OECD, 2013). It can be expected that
the determination of effect concentrations based on measured
concentrations will improve the predictive capacity of alternative
test systems (Knöbel et al., 2012; Tanneberger et al., 2013).
6.3. ADME
Significant differences in ADME (absorption, distribution,
metabolism and excretion) properties can be considered as major
limitation of alternative test systems, since they impact on the
internal concentration, the chemical concentrations at the target
site (s). This applies in principal to both in vitro and embryo tests.
However, it is anticipated that as primary cells and embryos more
closely resemble adult animals or intact organs, these should pro-
vide more similar metabolic properties than systems based on per-
manent cell cultures. In the case that in vitro–in vivo differences of
ADME are of minor relevance for the internal concentration, alter-
native test systems may provide a high confidence for predicting
the in vivo effect. For example, in the testing for skin or eye irrita-
tion required in human hazard assessment significant ADME ef-
fects are limited by the direct application of the test agent at its
target site in vivo (Leist et al., 2012). For other applications, ADME
differences need to be considered more carefully, e.g. by a detailed
characterisation of uptake and metabolism. For zebrafish embryos,
for instance, it was shown that ABC efflux transporter are active in
early developmental stages and able to reduce the uptake of chem-
icals (Fischer et al., 2013). Furthermore, transcriptional profiling of
zebrafish embryos has indicated that the majority of their cyto-
chrome P450 biotransformation enzymes are already expressed
and at least partially active during embryonic development
(Goldstone et al., 2010; Weigt et al., 2011, 2012). Furthermore,
the activity of metabolic enzymes is enhanced in fish embryos ex-
posed to chemicals (e.g. González-Doncel et al., 2011; Noury et al.,
2006). For primary fish hepatocytes and fish cell lines, some re-
search has been undertaken to characterise xenobiotic transport
and metabolising potencies (e.g. Escher et al., 2011; Thibaut
et al., 2009; Fischer et al., 2011). However, further research is
needed to fully understand the active transport and metabolic
capacity of in vitro alternatives and potential implications for the
prediction of toxic effects.
In case where there is a potential lack of relevant metabolic
capacities in alternative test systems, these can be combined with
a metabolic activation system (Busquet et al., 2008; Weigt et al.,
2010), such as liver microsomal preparations from an S9 extract
(i.e. the supernatant of a liver homogenate). Incubation with met-
abolic activation systems may also lead to the identification of po-
tential metabolites, an example of which is shown e.g. for
hydroxylation of brominated flame retardants (Hamers et al.,
2008). In such cases, synthesis of the metabolites could be per-
formed in vitro to account for the potential effect of biotransforma-
tion on toxicity or accumulation (Montaño et al., 2012), to prevent
underestimation of the hazard. The identification of metabolites
may, however, also indicate that the compound could be readily
inactivated and/or excreted by biotransformation. Moreover, com-
putational methods such as those included in the OECD QSAR tool-
box (http://www.qsartoolbox.org) can contribute by identifying
potential metabolites which could be included in in vitro testing
to account for a potential limited metabolic capacity of the alterna-
tive test system.
Understanding of ADME is also highly relevant for predicting
the bioconcentration or diffusion of chemicals in alternative ap-
proaches. Metabolism is a mitigating process, generally leading
to production of more water-soluble metabolites and enhanced
elimination of the toxicant from the exposed organism and
S. Scholz et al. / Regulatory Toxicology and Pharmacology 67 (2013) 506–530 523resulting in a lower BCF and/or effect concentrations. Hence, dif-
ferences in metabolising and xenobiotic transport capacities of
cultured cells and fish embryos compared to adult fish must be
taken into account when using these alternative models. Another
consideration for highly lipophilic substances is that uptake may
be underestimated due to different lipid concentrations present in
cells versus whole organisms. Furthermore, the role of transporter
proteins for bioconcentration in vivo and in vitro is not well
understood (Epel et al., 2008), and cellular uptake and elimination
by active transport may result in discrepancies of bioconcentra-
tion and effect concentrations in vivo and in alternative experi-
mental test systems. For instance, ABC transporter expression
and activity levels differ between permanent fish cell lines and
the tissue these cell lines were derived from (Fischer et al.,
2011). Discrepancies between fish embryos and later life stages
may result from interference by the yolk. It was shown that very
lipophilic compounds concentrate in the yolk sac leading to
higher internal exposure while compounds with log Kow < 5
disappear faster from the larvae than expected by diffusion and
hence, leading to lower than expected tissue residues (Foekema
et al., 2012).
The extrapolation of responses measured in vitro to those seen
in vivo would principally requires knowledge of the actual chemi-
cal concentrations at the target sites, which is usually not mea-
sured neither in vivo nor in vitro. Fortunately, as indicated by the
high correlation of fish embryos and fill cell lines with acute fish
toxicity, the internal target site concentrations can be expected
to be similar for many compounds. This could be anticipated given
similar exposure pathways based on a partition equilibrium with
an aqueous test medium. However, this is not a reason to be com-
placent and internal concentration analysis is recommended to
help to identify compounds for which the fish embryo or cell lines
may underestimate the acute toxicity. In addition, support of phar-
macokinetic models, prediction of internal concentrations could
provide a framework to improve the in vitro–in vivo link. This
has been successfully performed with the extrapolation of
in vitro estrogenicity values to in vivo effects by including ADME
parameters determined in vitro as well (Punt et al., 2013). Further-
more, a detailed toxicokinetic/pharmacokinetic understanding and
appropriate PBPK modelling can also contribute to the reduction of
animal test numbers, if in vivo models are continued to be used
(i.e. by providing a better estimation of the concentrations likely
causing an effect, the number of test concentration could be
reduced).6.4. Validation
Once an alternative approach has been demonstrated to provide
a promising predictive capacity and to be scientifically relevant,
the major limiting step for developing an OECD guideline and its
wider application is its validation. The fish embryo acute toxicity
test provides an appropriate example. The excellent correlation
to acute fish toxicity was long known (Nagel, 2002). However, only
recently, after a validation study had been successfully completed
(OECD, 2012g), an appropriate testing guideline of the Fish Embryo
Acute Toxicity Test (FET) has been adopted by the OECD (OECD TG
236). For the area of environmental risk assessment, the FET is the
only alternative method that has successfully been validated. This
may be set to change as a recent study has demonstrated that the
use of a fish gill cell line for testing acute fish toxicity is scientifi-
cally relevant and after optimisation (e.g. bioavailability in cell cul-
tures, role of the mode of action and physico-chemical properties
of test compounds, correlation between cell EC50 and fish LC50),the test is now ready to proceed to validation (Tanneberger et al.,
2013).
Validation is not always essential as this may not be needed
for the use of an alternative test method in a weight-of-evidence
approach. However, it is required for its development into an
OECD test guideline or other specific regulatory test guidelines
(see Text Box 2 on validation of alternative methods for details).
The validation process could delay the adoption of an OECD
guideline, if results on robustness,, intra- and inter-laboratory
calibration studies do not provide enough confidence in the
method.Validation of alternative methods
Alternative testing methods and strategies can be used
and accepted without validation – at least within a weight-
of-evident approach. However, for an international mutual
acceptance for hazard identification and risk assessment, suc-
cessful validation and subsequent adoption as OECD test
guideline are considered mandatory. The validation process
provides evidence for the reliability and relevance of the ap-
proach with respect to a particular purpose. Depending on
the type of test method developed (in vitro, QSAR, ‘omics’-
based, etc.), specific requirements are applicable. Various
organisations (e.g. OECD and EURL ECVAM) have provided
guidance documents on validation principles for new test ap-
proaches in hazard assessment (OECD, 2007a, 2005; Curren
et al., 1995; Balls et al., 1995; Hartung et al., 2004). The OECD
has outlined these principles – also known as SOLNA princi-
ples (OECD, 1996) – as follows:
(1) The rationale for the test method should be available.
(2) The relationship between the test method’s end-
point(s) and the (biological) phenomenon of interest
should be described.
(3) A detailed protocol for the test method should be
available.
(4) The intra- and inter-laboratory reproducibility of the
test method should be demonstrated.
(5) Demonstration of the test method’s performance
should be based on the testing of reference chemicals
representative of the types of substances for which the
test method will be used.
(6) The performance of the test method should have been
evaluated in relation to the relevant information from
the species of concern and existing relevant toxicity
testing data.
(7) Ideally, all data supporting the validity of a test method
should have been obtained in accordance with the
principles of GLP.
All data supporting the assessment of the validity of the test
method should be available for expert review.Due to the early stage of the development of experimental
alternative approaches to chronic toxicity tests, a validation of
potential alternatives is not foreseen at present. It is hoped that
perspective candidate assays for validation will probably evolve
from the AOP research where there is emphasis on finding key
endpoints which will provide sufficient predictive capacity for
higher organism in vivo effects. This would lead to the develop-
ment of AOP-targeted alternative test systems (Hartung et al.,
2013a). However, the AOP concept differs fundamentally from
38 The EFSA conclusions on pesticides are freely available via the EFSA webpage
http://www.efsa.europa.eu/en/publications.htm. More details are available on
request via the Draft Assessment Reports.
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points and, hence, validation schemes require adaptation to this
concept.
Validation schemes for non-testing approaches have already
been proposed (OECD, 2007a), but they still need to be improved.
This is especially true for standardized reporting, where clear guid-
ance and/or recommendations with regard to the new OECD guide-
lines are needed (OECD, 2007a). Validation may also be a problem
for some particular QSAR models which are incorporated into com-
plex existing tools such as ECOSAR. Such an integration does not
allow proper access to individual QSARs and their appropriate val-
idation on an individual basis (Kaiser et al., 1999).
Given the relevance of validation for regulatory acceptance, as-
pects of validation should be considered early in the development
of alternative assays in order to accelerate potential subsequent
validation. It is, therefore, important to instruct scientists involved
in the development of alternatives and acquaint them with valida-
tion needs. Protagonists of methods should also include the con-
cept of ‘applicability domains’ so that the limitations of a
particular alternative method are identified at the outset. A critical
observation is that research funding schemes in Europe and world-
wide usually do not support validation studies for alternative tests.
This may partially explain the long time period between the initial
development of an alternative approach and its final validation.
Validation can be time-consuming, costly and generally requires
voluntary participation and internal resources from participants.
It appears that the missing link once alternatives have been devel-
oped still remains the step between proof of concept and valida-
tion. It is obvious that there is a need to find mechanisms to help
fund and thereby speed up the validation of promising alternative
test methods. Also, until validated and harmonised testing proto-
cols are available, alternative testing approaches should at least
be used in weight-of-evidence perspective.
6.5. Availability of reference in vivodata
Availability of high quality in vivo data has been identified as
one of the major limitations, since these are required as a training
set or to be used as benchmarks both in the development and val-
idation phases to demonstrate the credibility of alternative testing
approaches (experimental and non-testing). Increasing the avail-
ability and/or facilitating the access to existing in vivo toxicity data
can be considered as a prime action to foster the development and
application of alternatives.
The acute fish toxicity test provides an example of how the
availability of a curated and validated data base for one species –
the fathead minnow – including more than 630 compounds has
supported the development of various alternative experimental
and non-testing methods (Russom et al., 1997; Lammer et al.,
2009b; Tanneberger et al., 2013; Schüürmann et al., 2011). For
chronic effects, however, such a database does not currently exist.
Some initiatives have been taken to try and redress this problem.
For example there are published evaluations of fish early life-stage
toxicity data which have been based on a coded set of proprietary
compounds for which appropriate information has been provided
during their registration or was provided by industry to a contract
researcher (Ahlers et al., 2006; Oris et al., 2012). However, if high
quality data are not publicly available and non-coded, it is difficult
to identify outliers and improve the models. Some approaches,
however, such as the Threshold (Step-Down) Approach for the
reduction of acute fish toxicity tests can be already sufficiently
evaluated with coded data sets (Jeram et al., 2005).
High quality data already exists at least partially, e.g. in the
ECHA, EFSA (European Food Safety Authority) or EMA (European
Medicines Agency) dossiers provided for the registration of chem-
icals, plant protection products and pharmaceuticals. Recently, theOECD and ECHA have jointly developed a web-based search tool to
facilitate access and search of REACH dossier data (Wittwehr, 2011,
http://www.echemportal.org). Furthermore, other databases such
as the US-EPA ECOTOX database are linked to the eChemPortal.
Also, ECETOC (2013) is compiling REACH dossier data into a data-
base, and EFSA makes information on PPPs available.38 These tools
and databases are expected to greatly facilitate the establishment of
animal test benchmarks for the development of alternative testing
strategies. However, despite the principal availability, the data are
usually not provided in an appropriately structured database format.
Furthermore, data summaries are provided but in order to fully ex-
plore the data for development of alternative testing strategies ac-
cess to raw data ideally via extended, uniform sets of toxicity data
(e.g. from registration dossiers of industry) in a user-friendly format
would be needed. If an analysis of existing data revealed a significant
restriction of access due to intellectual property rights, a potential
revision of international regulations aiming at facilitating data ac-
cess might be considered. For instance, data should be made acces-
sible at least for approved governmental organisations or public
research institutions, if needed through a broker to mitigate con-
cerns around commercial sensitivity. Experience has shown that
use of an ‘honest broker’ to facilitate data sharing, but maintain con-
fidentiality, can be acceptable to academic and industrial partners –
and can enable the development of an evidence base to support
arguments for changes in practice (Robinson et al., 2008; Chapman
et al., 2012; Chapman et al., 2010; Chapman et al., 2009; Oris
et al., 2012). A further possibility is to restrict the use of in silico tools
such as the software SARpy (Ferrari et al., 2013) on in-house data. In
this way industry does not need to disclose the structures of confi-
dential substances and toxicity values but can provide the model,
i.e. a set of rules, like structural alerts. These rules can be used with-
out disseminating the structures.
Finally, it should be recognised that variability and poor exper-
imental design of currently conducted in vivo assays may confound
the estimation of the predictive capacities of alternative ap-
proaches. Therefore, improvement and refinement of existing ani-
mal test design would also indirectly contribute to progress on the
development of alternative assays.
7. General conclusions
There are various areas in the development of alternative test-
ing approaches in environmental hazard and risk assessment that
require future action and research. As outlined above, they appear
to apply to many endpoints, regardless of whether testing or non-
testing approaches are considered. These include the need for a de-
tailed mechanistic understanding, e.g. for the exploitation of the
AOP concept, as well as knowledge on bioavailability and ADME
of chemicals in vivo and in vitro. However equally important for
the development of alternatives is the availability of high quality
in vivo reference data. For the final acceptance of a scientifically va-
lid approach, successful validation and availability of internation-
ally accepted test guidelines is a prerequisite.
It is now generally accepted that it is difficult to replace an ani-
mal test by a single experimental or non-testing approach. There-
fore, ITS can provide the operational means to combine the
different promising alternative methods in a powerful and predic-
tive approach that allows significant reduction of animal testing.
To achieve this goal it will be necessary to develop formalised ITSs
that allow industry and regulators to provide potential hazard
information with high reliability with at least the confidence of a
vertebrate test or endpoint.
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approaches in environmental risk assessments arises from the fact
that discussions about alternatives are frequently based upon ‘per-
ceptions’ and not exclusively based on scientific arguments. The
problem is that such perceptions may interfere with an objective
discussion of pros and cons of various alternative approaches.
The best (and only) option to overcome emotions and conserva-
tism are, of course, an even more convincing outcome from valida-
tion projects and more striking scientific arguments. Moreover,
continuous information and education of a broad public including
academics, industry and regulators is required to create a better
understanding of the opportunities and potential applicability of
new alternative methods. If a broad consensus on these issues can-
not be achieved, the future for widespread adoption of alternative
approaches in environmental risk assessment will remain an admi-
rable, but distant goal.
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